Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.

Pegaptanib is the only therapy approved by the Food and Drug Administration of the United States for the treatment of all neovascular AMD and represents a valuable addition to the hitherto limited options available for patients.